Introduction
Stroke is the most common cause of symptomatic epilepsy in older adults and status epilepticus (SE) can be a presenting clinical feature of acute stroke. 1, 2 Seizures and SE represent a diagnostic challenge in critically ill patients as frequently manifest with only subtle signs or are entirely non convulsive (subclinical). 3 Of note, in comatose patients with non convulsive status epilepticus (NCSE), 20% had ischaemic stroke. 3 Benzodiazepines have an established role as first line therapy for SE in many clinical settings; however, excessive benzodiazepines dosage in SE treatment is related to higher respiratory depression risk and longer hospitalisation, potentially exposing patients to additional complications and costs. 4 For these reasons the role of alternatives to standard AEDs therapy for SE treatment (e.g. benzodiazepines, PHT, barbiturates) deserves special attention in this population of frail patients due to the fewer potential severe adverse effects and the low interaction potential. 5, 6 We report our experience on intravenous (iv) LCM as a treatment option in post-stroke NCSE in elderly patients.
Methods
This was an observational study on patients treated with LCM as initial treatment (i.e. patients were directly started on LCM) for post-stroke NCSE. The IRB approved the study and granted a waiver of informed consent. Patients referred to the Stroke Unit within a period of two years were recruited in this study according to the following inclusion criteria: (1) ischaemic stroke occurring in patients !65 years of age and documented through brain CT/MRI; (2) a video-EEG documented SE; (3) no other concomitant conditions potentially responsible of epilepsy (alcohol abuse; Purpose: To evaluate the efficacy and safety of intravenously administered lacosamide (iv LCM) in poststroke non convulsive status epilepticus (NCSE) in elderly patients. Methods: We enrolled 16 patients (7 M/9 F; 77 AE 7 years of age) with NCSE. iv LCM was used in all the patients as initial treatment (i.e. patients were directly started on LCM) at a loading dose of 400 mg over 30 min, followed by a mean maintenance dose of 400 mg per day. iv LCM was considered as effective in patients who experience no NCSE for 24 h following treatment, as evaluated by EEG recording and clinical observation. Results: LCM was effective in treating NCSE in eight of the sixteen patients in whom epileptic activity disappeared (7/8) or was significantly reduced (1/8) within 45-60 min after administration. None of these patients relapsed in the following 24 h. No adverse events were observed. A partial anterior circulation syndrome (PACS) was present in 10 patients while a total anterior circulation syndrome (TACS) in six. Conclusions: This pilot study suggests that LCM exhibits safety and efficacy profiles which make it an optimal candidate as a first-choice drug against post-stroke NCSE in elderly patients. A prospective comparative trial is needed to confirm these preliminary data.
ß 2013 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved. psychotropic drugs; systemic/autoimmune diseases; dementia; electrolyte disturbance); (4) concomitant medical conditions in which the use of standard first-line AEDs (benzodiazepines, PHT) for SE were potentially unsafe because of likely side effects or toxic effects (hypotension, QT prolongation, arrhythmias, respiratory complications). Exclusion criteria were: (1) EEG monitoring showing only periodic discharges or rhythmic delta activity; and (2) previous treatment with LCM.
NCSE was defined as 30 min of continuous seizure activity without major motor phenomena. 7 Consciousness was categorised as alert/confuse/somnolent versus stuporous/comatose. According to Kaplan, 8 EEG criteria for NCSE were: (1) repetitive focal or generalised spikes, polyspike, sharp waves, spike-andwave, or sharp-and-slow wave complexes at >2.5 Hz; (2) above, with discharges <2.5 Hz but with clinical improvement or baseline EEG after administration of AEDs. In all the patients, video-EEG monitoring, lasting at least 3 h and including ECG tracing to evaluate heart rate and RR interval, was performed while iv LCM was being administered. Furthermore, each patient subsequently underwent a follow-up video-EEG 12 and 24 h after the initial diagnosis and treatment of NCSE. iv LCM was used in all the patients at a loading dose of 400 mg over 30 min, followed by a mean maintenance dose of 400 mg per day. iv LCM was considered as effective in patients who experience no NCSE for 24 h following treatment, as evaluated by EEG recording and clinical observation. Symptoms were defined as absent, mild, moderate or severe/ intolerable.
Stroke severity was assessed at admission using the National Institutes of Health (NIH) Stroke Scale (NIHSS) score; clinical classification was assessed using the Oxfordshire Community Stroke Project criteria 9 ; stroke aetiology was classified using the TOAST criteria. 10 Neuroimaging data were summarised according to the arterial territory circulation involved (anterior or posterior) and the size of infarction (ASPECT score <8 for anterior and posterior circulation). 
Results
During the study period, on the basis of clinical and EEG monitoring, we enrolled 16 elderly patients with NCSE. Of these, 10/16 patients developed NCSE 7 days after stroke onset. Of note, NCSE was the first symptom of stroke onset in two patients. The observed symptoms were an altered mental status or agitation in patients with complex SE (9/16, 56.2%) while a speech disturbance or visual hallucinations were observed in patients with simple SE (7/16, 43.7%).
Based on neuroimaging (CT/MRI) data and clinical assessment, we diagnosed a partial anterior circulation syndrome (PACS) in 10 patients and a total anterior circulation syndrome (TACS) in six (Table 1) .
LCM was effective in treating NCSE in 8 out of 16 patients in whom epileptic activity disappeared (7/8) or was significantly reduced (1/8) in a time ranging from 45 to 60 min after administration (data not shown). None of these patients relapses in the subsequent 24 h. No significant adverse events were observed. No changes in heart rate or RR interval were observed during iv LCM treatment. Eight patients (50%) were nonresponders and were switched to another AED. In non responders, after the first trial with iv LCM 400 mg, cessation of NCSE was obtained with iv diazepam 10 mg (3 patients) or iv levetiracetam 20 mg/kg (3 patients) introduced as second-line treatment. In two patients NCSE was defined as refractory.
At the 9-month follow-up, seven of the eight patients in whom the drug had proved effective were still taking LCM 300 mg daily. One patient was lost at the follow-up.
Discussion
Despite a large amount of studies about pathophysiology and treatment of post stroke seizure have been written, [12] [13] [14] [15] little is known concerning the role of alternatives to standard first-line therapy for SE treatment and, in particular, in post-stroke NCSE. In the present study, LCM was effective as initial treatment in 50% of patients, a percentage in line with the success rate reported with LCM (i.e. 56%) for the treatment of SE. 16 Literature data suggest that current first-line treatment with i.v. lorazepam or PHT control about 60% and 40%, respectively of SE in the elderly, irrespective of its cause. 17 Interestingly, due to the high proportions of first-line treatment failure in patients with NCSE, rapid treatment escalation is advocated although randomised controlled trials for second line treatment are lacking. Treatment of NCSE in the elderly presents challenges and the aggressiveness and potential adverse effects of a treatment must be weighed against the detrimental effects of the condition. 4, 7, 18 For example, in ischaemic stroke, although a synergistic effect of injuries from SE and cerebral ischaemia may underlie increased mortality in those patients, treatment of NCSE with benzodiazepines and anaesthetics can cause substantial respiratory depression, hypotension, prolonged ICU stays, concurrent infection, and death.
7 The role of newer AEDs in the treatment of SE is of interest, especially in benzodiazepine-resistant SE and where PHT is deemed inappropriate due to comorbidity (i.e. hypotension, QT prolongation, arrhythmias). 5 Recently, the usefulness of the i.v.
LCM in the treatment of SE has been reported in several retrospective studies. 16, 19 Interestingly, Hö fler et al. 19 observed a clear order effect of i.v. LCM with decreasing success rates as SE progress. Thus, the authors suggest using LCM in the early or established stages of status and not in the refractory later stages. 19 We are aware of the limitations of this study, in particular the small number of patients and the uncontrolled design. Moreover, we do not have precise timing between the onset of symptoms to the beginning of iv LCM treatment. This is particularly important because several studies showed that time to onset of therapy is a strong predictor of treatment response. 7, 17 Therefore, at the present time, observations deriving from open studies and single-arm observations also deserve attention and may be useful to optimise the design of future controlled double-blind randomised studies. 20 In particular, our study may be an interesting precursor to the TRENdS Study currently examining the treatment of non convulsive seizures with iv LCM (ClinicalTrials.gov Identifier: NCT01458522). Despite of these limitations, our findings suggest that LCM may be a good candidate as an alternative choice drug against post-stroke NCSE in elderly patients and call for controlled studies to verify this preliminary data.
